• FONT A+ A-

Professor Laurence Lovat

Professor Laurence Lovat
Professor of Gastroenterology & Biophotonics

Professor Lovat was educated at University College London School of Medicine. He won a prestigious MRC Research Training Award to take an intercalated degree in Nutrition for which he was awarded 1st Class Honours. He then won an MRC Research Training Fellowship to do his PhD at the Royal Postgraduate Medical School at the Hammersmith Hospital (now part of Imperial College). He was appointed as a senior lecturer at University College London and a consultant at UCH in 1999.

Specialist in:
  • Indigestion
  • Barrett‘s Oesophagus
  • Crohn‘s Disease
  • Endoscopy
  • Therapeutic Endoscopy
  • Acid Reflux
  • Cancer Prevention
  • Irritable Bowel Syndrome
  • Colonoscopy
Training

Professor Lovat was a scholar at the City of London School. He qualified from University College Hospital Medical School having also gained a first class honours degree in nutrition. He received a prestigious MRC research fellowship to fund his PhD studies at the Royal Postgraduate Medical School. He then trained in advanced therapeutic endoscopy at University College London Hospitals and was appointed a Consultant Gastroenterologist & Senior Lecturer in 1999. He was appointed as the first Head of the newly established Research Department for Tissue and Energy at UCL and was awarded his professorship in 2014 based on the quality of his research into complications of acid reflux disease and minimally invasive treatment to prevent and treat oesophageal cancer.

National Bodies

He has been appointed to numerous national and international bodies:

  • 2000 – 2 Member, Committee, British Oesophago-Gastric Cancer Group (BASO)
  • 2002 – 5 Member, Oesophageal Section Committee, British Society of Gastroenterology
  • 2002 – 5 Member, Research Committee, British Society of Gastroenterology
  • 2002 – 4 Member, Fundraising Committee, Barrett’s Oesophagus Foundation
  • 2002 – Member, Scientific Advisory Group, UK Barrett’s Oesophagus Registry
  • 2003 – Member, UK National PDT Advisory Board
  • 2004 – Convenor and advisory board, PROBE (Patient Research Network for Oesophageal Cancer and Barrett’s Epithelium)
  • 2005 – Member, Scientific Advisory Committee, Barrett’s Oesophagus Foundation
  • 2006 – Topic Lead, Barrett’s Oesophagus, National Electronic Library for Health, Gastroenterology & Liver Diseases Specialist Library
  • 2006 – 7 Member, Evaluation Board, Gastroenterology & Hepatology Faculty, Faculty of 1000 Medicine
  • 2005 – 8 Member, Committee, Imaging and Advanced Technology Section, American Gastroenterology Association
  • 2005 – 8 Specialist Advisor to NICE’s Interventional Procedures Programme.
  • 2009 – 10 Member, NICE Guideline Development Group for Ablative Therapy in Barrett’s Oesophagus
Publications

2014

Weaver, JMJ; Š.Lovat LB et al Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nature Genetics 10.1038/ng.3013.

Zeki, S. S., Haidry, R., Justo-Rodriguez, M., Lovat, L. B., Wright, N. A., & McDonald, S. A. (2014). Squamous cell carcinoma after radiofrequency ablation for Barrett’s dysplasia. World J Gastroenterol, 20 (15), 4453-4456. doi:10.3748/wjg.v20.i15.4453

Liu X, Wong A, Kadri SR, Corovic A, O¹Donovan M, Lao-Sirieix P, Lovat LB, Burnham RW, Fitzgerald RC. (2014) Gastro-Esophageal Reflux Disease Symptoms and Demographic Factors as a Pre-Screening Tool for Barrett¹s Esophagus. PLoS ONE 9(4): e94163. doi:10.1371/journal.pone.0094163

2013

Dunn, J. M., Mackenzie, G. D., Banks, M. R., Mosse, C. A., Haidry, R., Green, S., . . . Lovat, L. B. (2013). A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett’s oesophagus. Lasers Med Sci, 28 (3), 707-715. doi:10.1007/s10103-012-1132-1

Butt, M. A., Oukrif, D., Haidry, R. J., Rashid, M., Khan, S. . U. . R., Pye, H., . . . Lovat, L. B. (2013). CHARACTERISATION OF OESOPHAGEAL MUC1 EXPRESSION IN THE PROGRESSION TO OESOPHAGEAL ADENOCARCINOMA. GUT, 62, A113-A114. doi:10.1136/gutjnl-2013-304907.249

Paterson, A. L., Fitzgerald, R. C., O’Donovan, M., Provenzano, E., Murray, L. J., Coleman, H. G., . . . Lovat, L. B. (2013).Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. Journal of Pathology, 230 (1), 118-128. doi:10.1002/path.4044

Zeki, S. S., Wright, N. A., McDonald, S. A. C., Haidry, R., Lovat, L. B., Graham, T. A., . . . Dunn, J. (2013). Clonal selection and persistence in dysplastic Barrett’s esophagus and intramucosal cancers after failed radiofrequency ablation. American Journal of Gastroenterology, 108 (10), 1584-1592. doi:10.1038/ajg.2013.238

Oukrif, D., Butt, M. A., Bloom, E. S., Haidry, R. J., Khan, S. . U. . R., Louis-Auguste, J., . . . Lovat, L. B. (2013). DNA PLOIDY ABNORMALITIES CORRELATE WITH INCREASING DEGREE OF DYSPLASIA IN CASES REFERRED TO A SPECIALIST CLINICAL IMAGE CYTOMETRY SERVICE FOR THE MANAGEMENT OF BARRETT’S OESOPHAGUS. GUT, 62, A113. doi:10.1136/gutjnl-2013-304907.248

Haidry, R. J., Butt, M., Louis-Auguste, J., Novelli, M., Lovat, L., & Banks, M. (2013). ENDOSCOPIC SUBMUCOSAL DISSECTION FOR EARLY GASTRIC NEOPLASIA; PROSPECTIVE OUTCOMES FROM A SINGLE TERTIARY CENTRE. GUT, 62, A228-A229. doi:10.1136/gutjnl-2013-304907.532

Butt, M. A., Haidry, R. J., Oukrif, D., Dunn, J., Bloom, E. S., Louis-Auguste, J., . . . Novelli, M. (2013). EXPRESSION OF POLO-LIKE KINASE 1 AND GEMININ IS UP-REGULATED IN THE SQUAMOUS-METAPLASIA-DYSPLASIA-CARCINOMA SEQUENCE AND CORRELATES WITH ANEUPLOIDY. GUT, 62, A114. doi:10.1136/gutjnl-2013-304907.251

Butt, M. A., Gandy, M., Haidry, R. J., Bloom, E. S., Mackie, S., Khan, M. S., . . . Novelli, M. (2013). HER2 POSITIVITY IN UPPER GASTROINTESTINAL TUMOURS IN A LARGE MULTI-CENTRE UK COHORT IDENTIFIES SIMILAR POSITIVITY RATES BUT DIFFERENT TRENDS THAN PREVIOUSLY REPORTED AND SUGGESTS NEW POTENTIAL AVENUES FOR HER2 THERAPIES. GUT, 62, A112-A113. doi:10.1136/gutjnl-2013-304907.247

Butt, M. A., De Sordi, L., Yahioglu, G., Moose, C., Battah, S., Stamati, I., . . . Lovat, L. B. (2013). PHOTODYNAMIC ANTIMICROBIAL CHEMOTHERAPY (PACT) SELECTIVELY KILLS CLOSTRIDIUM DIFFICILE OVER COLON CELLS AND IS EFFECTIVE AGAINST 5 HYPERVIRULENT STRAINS OF THE PATHOGEN. GUT, 62, A215. doi:10.1136/gutjnl-2013-304907.496

Haidry, R. J., Dunn, J. M., Butt, M. A., Burnell, M. G., Gupta, A., Green, S., . . . Lovat, L. B. (2013). Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology, 145(1), 87-95. doi:10.1053/j.gastro.2013.03.045

Haidry, R. J., Butt, M. A., Dunn, J., Banks, M., Gupta, A., Smart, H., . . . Lovat, L. B. (2013). Radiofrequency ablation for early oesophageal squamous neoplasia: Outcomes form United Kingdom registry. World J Gastroenterol, 19 (36), 6011-6019. doi:10.3748/wjg.v19.i36.6011

Butt, M. A., Bloom, E. S., Stamati, I., Haidry, R. J., Oukrif, D., Khan, S. . U. . R., . . . Lovat, L. B. (2013). SECOND GENERATION PHOTOSENSITISER BASED PHOTODYNAMIC THERAPY IS EFFICACIOUS AND PENETRATES TISSUE MORE DEEPLY THAN RADIOFREQUENCY AND CRYO- ABLATIVE THERAPIES, OFFERING POTENTIAL FOR MORE INVASIVE GASTROINTESTINAL CANCERS. GUT, 62, A114. doi:10.1136/gutjnl-2013-304907.250

Butt, M. A., De Sordi, L., Yahioglu, G., Moose, C., Battah, S., Stamati, I., . . . Lovat, L. B. (2013). TWO PHASE PHOTODYNAMIC ANTIMICROBIAL CHEMOTHERAPY (PACT) COMBINED WITH GERMINANT THERAPY EFFECTIVELY TREATS CLOSTRIDIUM DIFFICILE AND THEIR SPORES THAT ARE RESISTANT TO ANTIBIOTICS. GUT, 62, A214-A215. doi:10.1136/gutjnl-2013-304907.495

Dunn, J. M., Mackenzie, G. D., Banks, M. R., Mosse, C. A., Haidry, R., Green, S., . . . Lovat, L. B. (2013). A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett’s oesophagus. Lasers Med Sci, 28 (3), 707-715. doi:10.1007/s10103-012-1132-1

Paterson, A. L., O’Donovan, M., Provenzano, E., Murray, L. J., Coleman, H. G., Johnson, B. T., . . . Fitzgerald, R. C. (2013). Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. Journal of Pathology, 230 (1), 118-128.

Haidry, R. J., Dunn, J. M., Butt, M. A., Burnell, M. G., Gupta, A., Green, S., . . . Lovat, L. B. (2013). Radiofrequency Ablation and Endoscopic Mucosal Resection for Dysplastic Barrett’s Esophagus and Early Esophageal Adenocarcinoma: Outcomes of the UK National Halo RFA Registry. Gastroenterology, 145 (1), 87-95. doi:10.1053/j.gastro.2013.03.045

2012

Butt, M. A., Pye, H., Haidry, R. J., Oukrif, D., Rashid, M., Banks, M. R., . . . Lovat, L. B. (2012). ABERRANTLY GLYCOSYLATED MUC1 AS A POTENTIAL THERAPEUTIC TARGET FOR BARRETT’S WITH HIGH GRADE DYSPLASIA AND PRIMARY AND METASTATIC OESOPHAGEAL ADENOCARCINOMA. GUT, 61, A301. doi:10.1136/gutjnl-2012-302514d.11

Bennett, C., Vakil, N., Bergman, J., Harrison, R., Odze, R., Vieth, M., . . . Jankowski, J. A. (2012). Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology, 143 (2), 336-346. doi:10.1053/j.gastro.2012.04.032

Haidry, R. J., Dunn, J., Banks, M., Gupta, A., Butt, M. A., Smart, H., . . . Lovat, L. B. (2012). HALO RADIOFREQUENCY ABLATION FOR HIGH GRADE DYSPLASIA AND EARLY MUCOSAL NEOPLASIA ARISING IN BARRETT’S OESOPHAGUS: INTERIM RESULTS FORM THE UK HALO RADIOFREQUENCY ABLATION REGISTRY. GUT, 61, A308. doi:10.1136/gutjnl-2012-302514d.28

Butt, M. A., Haidry, R. J., Oukrif, D., Pye, H., Stamati, I., Yahioglu, G., . . . Lovat, L. B. (2012). HER2 EXPRESSION IN THE BARRETT’S METAPLASIA-DYSPLASIA-CARCINOMA SEQUENCE AND POTENTIAL TARGETING IN VITRO WITH THE SINGLE CHAIN ANTIBODY FRAGMENT C6.5. GUT, 61, A302-A303. doi:10.1136/gutjnl-2012-302514d.15

Butt, M. A., Pye, H., Stamati, I., Yahioglu, G., Haidry, R. J., Oukrif, D., . . . Lovat, L. B. (2012). IN VITRO CHARACTERISATION OF ABERRANTLY GLYCOSYLATED MUC1 BINDING-PS1 PHOTOIMMUNOCONJUGATES FOR OESOPHAGEAL ADENOCARCINOMA TARGETED PHOTODYNAMIC THERAPY IN PRIMARY AND METASTATIC DISEASE. GUT, 61, A301. doi:10.1136/gutjnl-2012-302514d.12

Haidry, R. J., Lovat, L. B., Banks, M., Gupta, A., Butt, M. A., Novelli, M., . . . Rich, P. (2012). INFRARED SPECTROSCOPY ACURATELY DETECTS BARRETT’S MUCOSA BIOPSY SPECIMENS EX VIVO. GUT, 61, A307. doi:10.1136/gutjnl-2012-302514d.26

Bird-Lieberman, E. L., Neves, A. A., Lao-Sirieix, P., O’Donovan, M., Novelli, M., Lovat, L. B., . . . Fitzgerald, R. C. (2012). Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett’s esophagus. Nat Med, 18 (2), 315-321. doi:10.1038/nm.2616

Wallace, M. B., Crook, J., Saunders, M. D., Lovat, L., Coron, E., Waxman, I., . . . Wolfsen, H. C. (2012). Multicenter, Randomized Controlled Trial of Confocal Laser Endomicroscopy Assessment of Residual Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia in Barrett’s Esophagus (Clean Margin Trial). GASTROINTESTINAL ENDOSCOPY, 75 (4), 174.

Wallace, M. B., Crook, J. E., Saunders, M., Lovat, L., Coron, E., Waxman, I., . . . Wolfsen, H. C. (2012). Multicenter, randomized, controlled trial of confocal laser endomicroscopy assessment of residual metaplasia after mucosal ablation or resection of GI neoplasia in Barrett’s esophagus. Gastrointestinal Endoscopy, 76 (3), 539-547e1.

Butt, M. A., Haidry, R. J., Oukrif, D., Dunn, J. M., Gupta, A., Bhatt, M., . . . Novelli, M. R. (2012). POLO-LIKE KINASE 1 EXPRESSION PREDICTS ANEUPLOIDY IN THE BARRETT’S METAPLASIA-DYSPLASIA-CARCINOMA SEQUENCE. GUT, 61, A302. doi:10.1136/gutjnl-2012-302514d.14

ird-Lieberman, E. L., Dunn, J. M., Coleman, H. G., Lao-Sirieix, P., Oukrif, D., Moore, C. E., . . . Fitzgerald, R. C. (2012). Population-based study reveals new risk-stratification biomarker panel for Barrett’s esophagus. Gastroenterology, 143 (4), 927-935.e3.

Allain, B., Hu, M., Lovat, L. B., Cook, R. J., Vercauteren, T., Ourselin, S., & Hawkes, D. J. (2012). Re-localisation of a biopsy site in endoscopic images and characterisation of its uncertainty. Med Image Anal, 16 (2), 482-496. doi:10.1016/j.media.2011.11.005

Butt, M. A., Stamati, I., Pye, H., Yahioglu, G., Haidry, R. J., Oukrif, D., . . . Lovat, L. B. (2012). SELECTIVE CYTOTOXICITY OF ABERRANTLY GLYCOSYLATED MUC1 BINDING-PS1 PHOTOIMMUNOCONJUGATES FOR OESOPHAGEAL ADENOCARCINOMA TARGETED PHOTODYNAMIC THERAPY IN PRIMARY AND METASTATIC DISEASE. GUT, 61, A302. doi:10.1136/gutjnl-2012-302514d.13

2011

Dunn, J. M., Mackenzie, G. D., Thorpe, S., Austwick, M., Mosse, C. A., Oukrif, D., . . . Lovat, L. B. (2011). A RANDOMISED CONTROLLED TRIAL OF ALA VERSUS PHOTOFRIN PDT FOR HIGH GRADE DYSPLASIA IN BARRETT’S OESOPHAGUS. GUT, 60, A172. B M J PUBLISHING GROUP. doi:10.1136/gut.2011.239301.365

Dunn, J. M., Mackenzie, G. D., Thorpe, S., Austwick, M., Mosse, C. A., Oukrif, D., . . . Lovat, L. (2011). A Randomised Controlled Trial of ALA V Photofrin PDT for High Grade Dysplasia in Barrett’s Esophagus. GASTROENTEROLOGY, 140 (5), S215-S216. W B SAUNDERS CO-ELSEVIER INC.

Sellaturay, P., Haidry, R., Dunn, J., Green, S., Rodriguez-Justo, M., Winstanley, A., . . . Lovat, L. (2011). APPROPRIATE STAGING RENDERS ABLATIVE THERAPY SAFE FOR HIGH GRADE DYSPLASIA IN BARRETT’S OESOPHAGUS. GUT, 60. B M J PUBLISHING GROUP. doi:10.1136/gut.2011.239301.424

Haidry, R., Butt, M. A., & Lovat, L. B. (2011). Advances in diagnostic endoscopy. Medicine, 39 (5), 279-283.

Dunn, J. M., Hveem, T., Pretorius, M., Oukrif, D., Nielsen, B., Albregtsen, F., . . . Danielsen, H. E. (2011). Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett’s oesophagus. Br J Cancer, 105 (8), 1218-1223. doi:10.1038/bjc.2011.353

Banks, M. R., Haidry, R., Butt, M. A., Whitley, L., Stein, J., Langmead, L., . . . Lovat, L. B. (2011). High resolution colonoscopy in a bowel cancer screening program improves polyp detection. World J Gastroenterol, 17 (38), 4308-4313. doi:10.3748/wjg.v17.i38.4308

Dunn, J. M., Bird-Lieberman, E. L., Coleman, H. G., Oukrif, D., Arthur, K., Lao-Sirieix, P., . . . NIBR Study Grp. (2011). IMAGE CYTOMETRY DNA PLOIDY ABNORMALITIES ARE AN INDEPENDENT RISK FACTOR FOR CANCER PROGRESSION IN NON-DYSPLASTIC BARRETT’S OESOPHAGUS AND LOW GRADE DYSPLASIA: RESULTS OF THE NIBR STUDY. GUT, 60. B M J PUBLISHING GROUP.doi:10.1136/gut.2011.239301.367

Bird-Lieberman, E. L., Neves, A. A., Lao-Sirieix, P., O’Donovan, M., Lovat, L. B., Mahal, L. K., . . . Fitzgerald, R. C. (2011). MOLECULAR IMAGING VIA NOVEL APPLICATION OF FLUORESCENT LECTINS PERMITS RAPID ENDOSCOPIC IDENTIFICATION OF DYSPLASIA IN BARRETT’S OESOPHAGUS. GUT, 60, A170. B M J PUBLISHING GROUP. doi:10.1136/gut.2011.239301.361

Bird-Liebeman, E. L., Neves, A. A., Lao-Sirieix, P., O’Donovan, M., Novelli, M., Lovat, L., . . . Fitzgerald, R. (2011). Molecular Imaging via Novel Application of Fluorescent Lectins Permits Rapid Endoscopic Identification of Dysplasia in Barrett’s Esophagus. GASTROENTEROLOGY, 140 (5), S752. W B SAUNDERS CO-ELSEVIER INC.

AUSTWICK, M., Woodhams, J. H., Chalau, V., Mosse, C. A., Eliot, C., Lovat, L. B., . . . Bown, S. G. (2011). Optical Pharmacokinetics measurements of photosensitizer concentrations in vivo. Journal of Innovative Optical Health Sciences, 4 (2), 97-111. doi:10.1142/S1793545811001460

Austwick, M. R., Woodhams, J. H., Chalau, V., Mosse, C. A., Eliot, C., Lovat, L., . . . Bown, S. G. (2011). Optical measurement of photosensitizer concentration in vivo. Journal of Innovative Optical Health Sciences, 4 (2), 97-111.

Bird-Lieberman, E. L., Dunn, J. M., Lao-Sirieix, P., Mullholland, H. G., Moore, C. E., Arthur, K., . . . Fitzgerald, R. C. (2011). PHASE 2 AND PHASE 3 MULTICENTRE STUDIES DEMONSTRATE THE POTENTIAL FOR GLYCANS AS PREDICTIVE BIOMARKERS IN BARRETT’S OESOPHAGUS. GUT, 60. B M J PUBLISHING GROUP. doi:10.1136/gut.2011.239301.360

Dunn, J. M., McDonald, S. A., Oukrif, D., Haidry, R. J., Butt, M. A., Lovat, E., . . . Novelli, M. R. (2011). PLK-1 IS UPREGULATED IN BARRETT’S ADENOCARCINOMA AND IS A SURROGATE MARKER OF ANEUPLOIDY. GUT, 60. B M J PUBLISHING GROUP. doi:10.1136/gut.2011.239301.366

Banks, M., Haidry, R., Whitley, L., Stein, J., Langmead, L., Bloom, S., . . . Lovat, L. (2011). POLYP DETECTION IS IMPROVED BY MEGAPIXEL WHITE LIGHT HIGH RESOLUTION COLONOSCOPY IN THE UK NATIONAL BOWEL CANCER SCREENING PROGRAM. GUT, 60, A190. B M J PUBLISHING GROUP. doi:10.1136/gut.2011.239301.402

Dunn, J. M., Bird-Lieberman, E. L., Lao-Sirieix, P., Mulholland, H. G., Oukrif, D., Walker, E. C., . . . Fitzgerald, R. (2011). Phase 3 Population-Based Study Reveals New Risk-Stratification Biomarker Panel for Barrett’s Esophagus. GASTROENTEROLOGY, 140 (5), S136. W B SAUNDERS CO-ELSEVIER INC.

Huggett, M. T., Baddeley, R. N. B., Sandanayake, N. S., Webster, G. J. M., Bown, S. G., Lovat, L. B., . . . Pereira, S. P. (2011). Photodynamic therapy of pancreatic cancer and elastic scattering spectroscopy of the duodenal mucosa for the detection of pancreaticobiliary malignancy. OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XX, 7886. doi:10.1117/12.874053

Huggett, M. T., Baddeley, R. N. B., Sandanayake, N. S., Webster, G. J. M., Bown, S. G., Lovat, L. B., . . . Pereira, S. P. (2011). Photodynamic therapy of pancreatic cancer and elastic scattering spectroscopy of the duodenal mucosa for the detection of pancreaticobiliary malignancy. Progress in Biomedical Optics and Imaging – Proceedings of SPIE, 7886.

Dunn, J. M., McDonald, S. A., Oukrif, D., Haidry, R. J., Butt, M. A., Lovat, L., . . . Novelli, M. (2011). Plk-1 is Upregulated in Barrett’s Adenocarcinoma and is a Surrogate Marker of Aneuploidy. GASTROENTEROLOGY, 140 (5), S667. W B SAUNDERS CO-ELSEVIER INC.

Banks, M. R., Haidry, R. J., Whitley, L., Stein, J., Langrnead, L., Bloom, S. L., . . . Lovat, L. B. (2011). Polyp Detection is Improved by Megapixel White Light High Resolution Colonoscopy in the UK National Bowel Cancer Screening Program. GASTROENTEROLOGY, 140 (5), S559. W B SAUNDERS CO-ELSEVIER INC.

Haidry, R. J., Dunn, J. U., Thorpe, S., Fullarton, G., Smart, H., Bhandari, P., . . . Lovat, L. B. (2011). Radio Frequency Ablation is More Effective in Shorter Segments of Barrett’s Oesophagus for Eradication of High Grade Dysplasia/Intramucosal Cancer – Results From the UK RFA HALO Registry. GASTROENTEROLOGY, 140 (5), S215. W B SAUNDERS CO-ELSEVIER INC.

Dunn, J. M., Banks, M. R., Oukrif, D., Mackenzie, G. D., Thorpe, S., Rodriguez-Justo, M., . . . Lovat, L. B. (2011). Radiofrequency ablation is effective for the treatment of high-grade dysplasia in Barrett’s esophagus after failed photodynamic therapy. Endoscopy, 43 (7),627-630. doi:10.1055/s-0030-1256443

Allain, B., Hu, M., Lovat, L. B., Cook, R. J., Vercautran, T., Ourselin, S., & Hawkes, D. J. (2011). Re-localisation of a Biopsy Site in Endoscopic Images and Characterisation of its Uncertainty. Medical Image Analysis.

2010

Allain, B., Hu, M., Lovat, L. B., Cook, R. J., Vercauteren, T., Ourselin, S., & Hawkes, D. J. (2010). A system for biopsy site re-targeting with uncertainty in gastroenterology and oropharyngeal examinations. Med Image Comput Comput Assist Interv, 13 (Pt 2),514-521.

Dunn, J. M., Lovat, L. B., Pretorius, M. E., Oukrif, D., Hveem, T., Nielsen, B., . . . Danielsen, H. E. (2010). COMBINATION OF NUCLEAR TEXTURAL ANALYSIS AND IMAGE CYTOMETRIC DNA ANALYSIS IS MORE ACCURATE THAN IMAGE CYTOMETRIC DNA PLOIDY ANALYSIS ALONE FOR RISK STRATIFICATION IN BARRETT’S OESOPHAGUS. GUT, 59, A114-A115. B M J PUBLISHING GROUP. doi:10.1136/gut.2009.208983r

Dunn, J. M., Jiao, Y., Austwick, M., Mosse, C. A., Oukrif, D., Thorpe, S., . . . Lovat, L. B. (2010). ELASTIC SCATTERING SPECTROSCOPY IS HIGHLY ACCURATE FOR THE DETECTION OF HIGH-GRADE DYSPLASIA AND DNA PLOIDY ARISING IN BARRETT’S OESOPHAGUS USING A RED ENHANCED SPECTROMETER. GUT, 59, A115-A116. B M J PUBLISHING GROUP. doi:10.1136/gut.2009.208983t

Dunn, J. M., Thorpe, S., Fullarton, G. M., Smart, H., Penman, I., Patel, P., . . . Lovat, L. B. (2010). ENDOSCOPIC RADIOFREQUENCY ABLATION FOR HIGH-GRADE DYSPLASIA OR INTRAMUCOSAL CANCER IN BARRETT’S OESOPHAGUS – RESULTS FROM THE FIRST 100 PATIENTS ENROLLED IN THE UK HALO RADIOFREQUENCY ABLATION REGISTRY. GUT, 59, A115. B M J PUBLISHING GROUP. doi:10.1136/gut.2009.208983s

Dunn, J. M., Thorpe, S., Fullarton, G. M., Smart, H., Penman, I. D., Patel, P., . . . Lovat, L. (2010). Endoscopic Radiofrequency Ablation for HGD or IMC in Barrett’s Esophagus – Results From the First 100 Patients Enrolled in the UK RFA Registry. GASTROINTESTINAL ENDOSCOPY, 71 (5), AB176. MOSBY-ELSEVIER.

Dunn, J. M., Mackenzie, G. D., Oukrif, D., Mosse, C. A., Banks, M. R., Thorpe, S., . . . Lovat, L. B. (2010). Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett’s oesophagus following photodynamic therapy. Br J Cancer, 102 (11), 1608-1617. doi:10.1038/sj.bjc.6605688

Gupta, A., Dunn, J. M., Thorpe, S. M., Banks, M. R., Bown, S. G., & Lovat, L. B. (2010). PATTERN DISTRIBUTION OF BARRETT’S OESOPHAGUS BASED ON TWO-DIMENSIONAL RECONSTRUCTION OF MACROSCOPIC FINDINGS AT ENDOSCOPY. GUT, 59, A116. B M J PUBLISHING GROUP. doi:10.1136/gut.2009.208983u

Dunn, J., & Lovat, L. (2010). The role of endoscopic ultrasonography in Barrett’s esophagus and early esophageal cancer. Techniques in Gastrointestinal Endoscopy, 12 (1), 12-17.

2009

Allain,B., Hu,M., Lovat,L., Cook,R., Ourselin,S., Hawkes,D. (2009). Relocalisation method for an accurate matching of optical and histological biopsy sites in Barrett’s oesophagus. Gut 58, A508. ISSN: 0017-5749

Allain,B., Hu,M.X., Lovat,L.B., Ourselin,S., Cook,R., Hawkes,D.J. (2009). Biopsy Site Re-localisation based on the Computation of Epipolar Lines from Two Previous Endoscopic Images. MICCAI, Yang,G.Z., Hawkes,D.J., Rueckert,D. (ed.) Heidelberg:Springer, 5761, 491-498

Bown, Stephen G., Mackenzie, Gary D., Dunn, Jason M., Thorpe, Sally M., Lovat, Laurence B. (2009). ALA PDT for high grade dysplasia in Barrett’s oesophagus: review of a decade’s experience, Kessel, David H. (ed.) Seattle, WA, USA:SPIE, 7380 (1), 738018-738019 [Online]

Dunn,J.M., Fullarton,G., Thorpe,S.M., Novelli,M.R., Bown,S.G., Lovat,L. (2009). Radiofrequency ablation of high grade dysplasia in Barrett’s oesophagus after failed photodynamic therapy – results of the UK HALO RFA registry after one year. Gut 58, A48. ISSN: 0017-5749

Dunn,J.M., Thorpe,S., Novelli,M.R., Bown,S.G., Lovat,L.B. (2009). Initial results of radiofrequency ablation for the treatement of squamous high grade dysplasia of the oesophagus. Gut 58, A287. ISSN: 0017-5749

Dunn,J.M., Fullarton,G., Thorpe,S., Novelli,M., Bown,S.G., Lovat,L.B. (2009). RADIOFREQUENCY ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT’S OESOPHAGUS AFTER FAILED PHOTODYNAMIC THERAPY: FIRST RESULTS OF THE UK HALO RADIOFREQUENCY ABLATION REGISTRY. Gut 58, PT286. ISSN: 0017-5749

Dunn,J.M., Fullarton,G.M., Thorpe,S., Novelli,M., Bown,S.G., Lovat,L.B. (2009). Radiofrequency Ablation of High Grade Dysplasia in Barrett’s Oesophagus Is Safe and Effective After Failed Photodynamic Therapy – First Results of the UK HALO RFA Registry. Gastrointestinal Endoscopy 69(5), AB260. ISSN: 0016-5107

Dunn,J.M., Mackenzie,G.D., Oukrif,D., Mosse,C.A., Green,S., Chew,Y., Thorpe,S., Novelli,M., Bown,S.G., Lovat,L.B. (2009). DNA PLOIDY AS A PROGNOSTIC BIOMARKER AFTER AMINOLEVULINIC ACID PHOTODYNAMIC THERAPY FOR HIGH-GRADE DYSPLASIA IN BARRETT’S OESOPHAGUS. Gut 58, PT285. ISSN: 0017-5749

Dunn,J.M., Thorpe,S., Novelli,M., Bown,S.G., Lovat,L.B. (2009). Radiofrequency Ablation for the Treatment of Squamous High Grade Dysplasia of the Oesophagus- First Reported Series. Gastrointestinal Endoscopy 69(5), AB255. ISSN: 0016-5107

Mackenzie,G.D., Dunn,J.M., Selvasekar,C.R., Mosse,C.A., Thorpe,S.M., Novelli,M.R., Bown,S.G., Lovat,L.B. (2009). Optimal conditions for successful ablation of high-grade dysplasia in Barrett’s oesophagus using aminolaevulinic acid photodynamic therapy. Lasers in Medical Science 24(5), 729-734. ISSN: 0268-8921

Paterson,A.L., Provenzano,E.,O’Donovan,M., Davies,S.E., Novelli,M.R., Lovat,L.B., Fitzgerald,R.C. (2009). ERBB2 EXPRESSION IN OESOPHAGEAL ADENOCARCINOMA AND BARRETT’S OESOPHAGUS: DEMONSTRATING THE POTENTIAL FOR A PRE-EMPTIVE STRIKE. Gut 58, PT283. ISSN: 0017-5749 S

ilvanto,A., Novelli,M., Lovat,L.B. (2009). SIRT – an uncommon cause of gastroduodenal ulceration. Histopathology 55(1), 114-115. ISSN: 0309-0167

Thorpe,S., Dunn,J.M., Mackenzie,G.D., Mosse,C.A., Austwick,M., Bown,S.G., Lovat,L.B. (2009). Quality of life following ALA v Photofrin PDT for dysplastic Barrett’s oesophagus – preliminary results of a randomised controlled trial. Gut 58, A133. ISSN: 0017-5749

Zhu,Y., Fearn,T., Mackenzie,G., Clark,B., Dunn,J.M., Bigio,I.J., Bown,S.G., Lovat,L.B. (2009). Elastic scattering spectroscopy for detection of cancer risk in Barrett’s esophagus: experimental and clinical validation of error removal by orthogonal subtraction for increasing accuracy. Journal of Biomedical Optics 14(4), 044022. ISSN: 1083-3668

Grants
  • 1986: University of London AH Bygott Undergraduate Award in Community Medicine
  • 1986: International Foundation for Promotion of Nutrition Research and Nutrition Education Student Award (£1,200)
  • 1987: British Nutrition Foundation Student Award
  • 1987: Riker Laboratories Student Elective Prize
  • 1991: British Geriatric Society Senior Registrar Research Start Up Grant (£1,500)
  • 1994 Hammersmith SHA Research Grant (£9,500)
  • 2000: AstraZeneca Effect of Gastro-Oesophageal Reflux Treatment and Arousals in Patients with Obstructive Sleep Apnoea (£6,500)
  • 2000-2002: Association for International Cancer Research Photodynamic Therapy for the Treatment of Barrett’s oesophagus (£114,000)
  • 2002-2004: DUSA Pharmaceuticals Inc Randomised controlled trial of Photodynamic Therapy for High Grade Dysplasia in Barrett’s oesophagus (£101,000)
  • 2002-2004: National Translational Cancer Research Network (NTRAC). The role of cytokines in oesophageal mucosal repair following photodynamic therapy for Barrett’s oesophagus (£20,000)
  • 2003-2004: UCL Clinical Research and Development Committee (CRDC) Fast Track Grant: Elastic scattering spectroscopy as in vivo test for aneuploidy in Barrett’s oesophagus (£25,000)
  • 2004-2009: NIH – National Cancer Institute Network for Translational Research into Optical Imaging: Elastic scattering spectroscopy in the management of Barrett’s oesophagus – detection of dysplasia and monitoring of photodynamic therapy. ($545,000, £328,970)
  • 2005-2006: NIH – National Cancer Institute Network for Translational Research into Optical Imaging Development Grant: Elastic Scattering Spectroscopy to Detect Molecular Markers of Malignant Progression in Barrett’s oesophagus: Methods to Rapidly Prove the Principle (£36,790)
  • 2005-2007: Axcan Pharmaceuticals – Trial of Allopurinol to reduce skin phototoxicity after photodynamic therapy with Photofrin (£78,000)
  • 2007-2012: CRUK – Experimental Cancer Medicine Programme Grant £1,176,675: PI (29 Co-investigators).
  • 2008-2011: MRC – Biomarker qualification in Barrett’s oesophagus. MRC Grant G0601390 (Total £1,061,564, MRC contribution £436,677). PI. Lead applicant: Dr R Fitzgerald, Cambridge, Coapplicants: Prof L Murray, Belfast, Prof K Brindle, Dr B Johnston, Dr D McManus, Prof M Novelli, Dr C Patterson
  • 2008-2011: CRUK – Project Grant: Elastic Scattering Spectroscopy for diagnosis of dysplasia and aneuploidy in Barrett’s oesophagus £325,710: CI. Sponsor Reference C18515/A9022
  • 2008-2009: Given Imaging – Differentiation of squamous from columnar mucosa in the oesophagus using a reduced number of wavelengths £78,964
  • 2009-2010: Barrett’s Oesophagus Campaign – Building a Research Database to support the National Barrett’s Dysplasia Audit £10,000: CI
Locations

Professor Lovat sees patients in central London on a Monday afternoon and early evening and at the Wellington Diagnostics Centre in Golders Green on a Thursday afternoon and evening.

Fees

Professor Lovat is a fee assured BUPA consultant. He is also part of the BUPA Premier Consultant Partnership. Patients insured with BUPA should never encounter any shortfalls in their fees.

Prof. Lovat likes to his patients to be comfortable that there will not be unexpected fees. He therefore tries to work within the published fee schedules of all the other major UK private healthcare insurance companies. You should know however that with the very wide variety of private insurance schemes on the market, you may have personal liabilities. This is particularly common with WPA patients who often agree to pay a proportion of all fees. Please always check with your insurance company. If you would like a formal quote, we are happy to provide these.

For patients without insurance, and for people who have taken out insurance with insurance companies outside the UK, please request a formal quotation. We will usually ask you to pay us directly and reclaim the fees from your insurer.

Patient Reviews
Professor Laurence Lovat Reviews

More than 90% of patients who took our survey are ‘Very’ or ‘Extremely’ likely to recommend Professor Lovat

Professor Laurence Lovat Reviews

88% of patients who took our survey say Professor Lovat listens very or extremely well

Professor Laurence Lovat Reviews

More than 90% of patients who took our survey say Professor Lovat’s staff are very or extremely friendly